Core Insights - The Chinese biopharmaceutical industry is accelerating its development, transitioning from a "rapid expansion" phase (1.0 era) to a focus on "value and global competitiveness" (2.0 era) [1] - China has become the second-largest market for new drug launches globally and has established a leading position in disruptive technologies such as targeted protein degradation (TPD) [1] - The rapid growth of outbound licensing transactions reflects the industry's global competitiveness, with transaction volumes exceeding $50 billion from January to August 2025 [1] Industry Trends - The industry is experiencing a theme of differentiation and rational return, with China ranking among the top tier globally in areas like antibody-drug conjugates (ADC) and bispecific antibodies [1] - There is an increase in internal homogenization competition, prompting a shift in focus from storytelling to hard capabilities among companies [1] - The capital market is returning to rationality, with funding increasingly directed towards mid-to-late-stage projects and leading companies in validated sectors [1] Market Performance - The vaccine ETF (159643) rose by 1.2% on February 3, with over 100 million yuan net inflow in the past 10 days [1] - The vaccine ETF tracks the vaccine biotechnology index (980015), which includes listed companies involved in vaccine research, production, and related biotechnologies [1]